- Preparation method of substituted benzene sulfonyl chloride
-
The invention provides a preparation method of substituted benzene sulfonyl chloride, which comprises the following steps: carrying out diazotization reaction on an aniline compound with a structure as shown in a formula I to obtain fluoboric acid diazonium salt with a structure as shown in a formula II; obtaining substituted benzene sulfonyl chloride with a structure as shown in a formula III from the fluoboric acid diazonium salt with the structure as shown in the formula II; wherein R is selected from any one of ortho-chlorine, bromine, methyl, chloromethyl, bromomethyl, nitro, cyano, acetyl, meta-chlorine, bromine, methyl, chloromethyl, bromomethyl, nitro, cyano, acetyl, para-chlorine, bromine, methyl, chloromethyl, bromomethyl, nitro, cyano and acetyl. The preparation method of the substituted benzene sulfonyl chloride provided by the invention is simple in reaction process, easy to operate, ideal in effect and suitable for industrial production.
- -
-
Paragraph 0051-0054
(2021/05/08)
-
- An in situ combinatorial methodology to synthesize and screen chemical probes
-
Chemical probes that label proteins of interest in the context of complex biological samples are useful research tools. The reactive group that forms the covalent bond with the target protein has a large effect on the selectivity and selecting the appropriate group determines the success of a probe. We here report the development of a combinatorial methodology based on imine chemistry that enables straightforward in situ synthesis and screening of different reactive groups and thereby simplifies identification of probe leads. Using our methodology, we found chemical probes targeting BirA and chloramphenicol acetyl transferase, two proteins associated with antibacterial activity and resistance.
- Van Der Zouwen, Antonie J.,Lohse, Jonas,Wieske, Lianne H. E.,Hohmann, Katharina F.,Van Der Vlag, Ramon,Witte, Martin D.
-
supporting information
p. 2050 - 2053
(2019/02/19)
-
- Carbocation Catalyzed Bromination of Alkyl Arenes, a Chemoselective sp3 vs. sp2 C?H functionalization.
-
The versatility of the trityl cation (TrBF4) as a highly efficient Lewis acid organocatalyst is demonstrated in a light induced benzylic brominaion of alkyl-arenes under mild conditions. The reaction was conducted at ambient temperature under common hood light (55 W fluorescent light) with catalyst loadings down to 2.0 mol% using N-bromosuccinimide (NBS) as the brominating agent. The protocol is applicable to an extensive number of substrates to give benzyl bromides in good to excellent yields. In contrast to most previously reported strategies, this protocol does not require any radical initiator or extensive heating. For electron-rich alkyl-arenes, the trityl ion catalyzed bromination could be easily switched between benzylic sp3 C?H functionalization and arene sp2 C?H functionalization by simply alternating the solvent. This chemoselective switch allows for high substrate control and easy preparation of benzyl bromides and bromoarenes, respectively. The chemoselective switch was also applied in a one-pot reaction of 1-methylnaphthalene for direct introduction of both sp3 C?Br and sp2 C?Br functionality. (Figure presented.).
- Ni, Shengjun,El Remaily, Mahmoud Abd El Aleem Ali Ali,Franzén, Johan
-
supporting information
p. 4197 - 4204
(2018/09/25)
-
- Synthesis of novel N-(2-Hydroxyphenyl)arylsulfonamides as selective HDAC inhibitory and cytotoxic agents
-
Based on the finding that the 2-aminobenzamido group of MS-275 plays a crucial role in inhibiting HDACs through chelation of zinc existing at the active site of HDAC enzymes, novel N-(2-hydroxyphenyl)aryl-sulfonamide derivatives were synthesized for their potential ability to inhibit HDACs and evaluated for anticancer activity against human breast cancer cell line (MCF-7). Although the synthesized arylsulfonamides have failed to significantly inhibit total HDACs activity, phenyl carbamate-linked arylsulfonamide 10 and benzyl thiocarbamate-linked arylsulfonamide 15 exhibited good anticancer activities, which were only 4.3- and 3.6-fold lower anticancer activities, respectively, than MS-275 that is undergoing phase II clinical trials. These results suggest that these compounds may act as a selective HDAC inhibitor and probably N-(2-hydroxy-phenyl)sulfamoyl group may play an important role in interacting with HDAC enzymes through chelation of zinc ion.
- Kim, Jungsu,Chun, Pusoon,Moon, Hyung Ryong
-
p. 1487 - 1493
(2013/07/28)
-
- 4-PHENYL-5-OXO-1,4,5,6,7,8-HEXAHYDROQUINOLINE DERIVATIVES THE TREATMENT OF INFERTILITY
-
The present invention relates to 4-phenyl-5-oxo-l,4)5,6,7,8-hexahydroquinoline derivatives according to Formula I, Formula I or a pharmaceutically acceptable salt thereof, wherein R1 is (l-6C)alkyl, (2-6C)alkenyl or (2-6C)aDcynyl; R2, R3 are independently halogen, (l-4C)allcyl, (2-4C)alkenyl, (2-4C)- alkynyl, (1 -4C)aBcoxy, (3-4C)alkenyloxy or (3-4C)alkynyloxy; R4 is phenyl or (2-5C)- heteroaryl, both substituted with R7 and optionally substituted on the (hetero)aromatic ring with one or more substituents selected from hydroxy, amino, halogen, nitro, trifluoromethyl, cyano, (l-4C)alkyl, (l-4C)alkoxy , (l-4C)alkylthio and (di)(l-4C)- alkylamino. The invention also relates to pharmaceutical compositions comprising said derivatives, as well as to the use of these 4-phenyl-5-oxo-l, 4,5,6, 7,8-hexahydro- quinoline derivatives in therapy, more specifically for the treatment of infertility
- -
-
Page/Page column 53
(2010/11/24)
-
- Heterocyclic sulfonamide derivatives as antagonists of PAF and angiotensin II
-
Compounds of formula (I), wherein: A represents: a) a --VR6 group wherein v is --C(=O), --C(=O)O--, --CH2 O--, --CH2 OC(=O)--, --C(=S)--, --CH2 OC(=O)NH--, --C(=S)O--, --CH2 S--, --C(=O)NHSO2 --, --SO2 NHC(=O)-- or --CH2 OSiPh2 --; b) a --CH2 NR9 R10 group or a --CONR9 R10 group wherein each of R9 and R10 is independently hydrogen, -alkyl-, -alkenyl-, -alkynyl, -cycloalkyl, -cycloalkenyl, pyridyl (any of which may optionally be substituted) or a group --D as defined above or R9 and R10 together with the nitrogen atom to which they are attached form a nitrogen-containing heterocyclic ring; c) a group Y where Y is a 5- or 6-membered optionally substituted heterocyclic ring containing one or more heteroatoms selected from nitrogen, oxygen and sulphur; or d) a group --CH2 Y or --C(=O)NHY; where Y is as defined above; B represents a 5- or 6-membered heterocyclic ring containing one or more nitrogen atoms in its ring, are antagonists of platelet activating factor (PAF) and/or antagonists of angiotensin II.
- -
-
-
- 4-(1H-2-methylimidazo[4,5-c]pyridinylmethyl)phenylsulphonamide derivatives as antagonist of PAF
-
The present invention is directed to compounds of general formula I as well their pharmaceutically and veterinarily acceptable acid addition salts or hydrates thereof. The present invention is further directed to pharmaceutical and veterinary compositions containing the compounds of general formula I. The present compounds of general formula I are antagonist of platelet activating factor (PAF). Accordingly, the present invention is also directed to methods for preventing, treating or ameliorating in human or mammalian animals, various diseases or physiological conditions mediated by PAF.
- -
-
-
- Imidazo (4,5-C) pyridine derivatives as PAF antagonists
-
Compounds of formula I: STR1 wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and B are variables. These compounds are antagonists of platelet activating factor (PAF) and as such are useful in the treatment or amelioration of various diseases or disorders mediated by PAF.
- -
-
-
- Sulphonylbenzyl-substituted imidazoles
-
Sulphonylbenzyl-substituted imidazoles can be prepared by first reacting imidazolylaldehydes with sulphonylbenzyl compounds and then oxidising or reducing the aldehyde function in the customary manner. The sulphonylbenzyl-substituted imidazoles can be used as active compounds in medicaments.
- -
-
-
- Sulphonylbenzyl-substituted imidazopyridines
-
Sulphonylbenzyl-substituted imidazopyridines can be prepared by reacting correspondingly substituted imidazopyridines with sulphonylbenzyl compounds. The sulphonylbenzyl-substituted imidazopyridines can be employed as active compounds in medicaments, in particular for the treatment of hypertension and atherosclerosis.
- -
-
-
- Sulfonylbenzyl-substituted benzo- and pyridopyridones
-
Sulfonylbenzyl-substituted benzo- and pyridopyridones are prepared by reacting corresponding benzo- and pyridopyridones with sulphonylbenzyl compounds. The sulphonylbenzyl-substituted benzo- and pyridopyridones can be employed as active compounds in medicaments, in particular for the treatment of arterial hyper tension and atherosclerosis.
- -
-
-
- Certain sulfonamide heterobicyclic platelet activating factor antagonists
-
Compounds of general formula I; STR1 wherein: A1 is =N--, =CH-- or =CR1 --; A2 is =N--, =CH-- or =CR2 --; provided that, when one of A1 and A2 is a nitrogen atom, the other of A1 and A2 is other than a nitrogen atom; wherein the other variables are as defined in the specification and their pharmaceutically and veterinarily acceptable acid addition salts and hydrates are antagonists of platelet activating factor (PAF) and as such are useful in the treatment or amelioration of various diseases or disorders mediated by PAF.
- -
-
-
- Thiazolidinedione hypoglycemic agents
-
Hypoglycemic thiazolidine-2,4-dione derivatives of the formula STR1 wherein the dotted line represents a bond or no bond; A and B are each independently CH or N, with the proviso that when A or B is N, the other is CH; X is S, SO, SO2, CH2, CHOH or CO; n is 0 or 1; Y is CHR1 or NR2, with the proviso that when n is 1 and Y is NR2, X is SO2 or CO; Z is CHR3, CH2 CH2, CH=CH, STR2 OCH2, SCH2, SOCH2 or SO2 CH2 ; R, R1, R2 and R3 are each independently hydrogen or methyl; and X1 and X2 are each independently hydrogen, methyl, trifluoromethyl, phenyl, benzyl, hydroxy, methoxy, phenoxy, benzyloxy, bromo, chloro or fluoro; a pharmaceutically-acceptable cationic salt thereof; or a pharmaceutically-acceptable acid addition salt thereof when A or B is N.
- -
-
-
- A novel series of selective leukotriene antagonists: Exploration and optimization of the acidic region in 1,6-disubstituted indoles and indazoles
-
A systematic structure-activity exploration of the carboxylic acid region in a series of indole- or indazole-derived leukotriene antagonists 1 led to several discoveries. Use of the 3-methoxy-p-tolyl fragment (illustrated in acid 1) for connecting the indole and the acidic site provides the most potent carboxylic acids 1, tetrazoles 20, and aryl sulfonimides 21. The aryl sulfonimides are 5-500 times more potent (in vitro and/or in vivo) than the corresponding carboxylic acids 1. The o-tolyl sulfonimides such as 114 show greater oral potency than the phenyl sulfonimides at a given level of in vitro activity. Acidic keto sulfone derivatives 10 (Nu = CH(CO2CH3)SO2Ph) mimic the activity of the sulfonimides.
- Yee,Bernstein,Adams,Brown,Cronk,Hebbel,Vacek,Krell,Snyder
-
p. 2437 - 2451
(2007/10/02)
-
- Toners and yellow dye compounds used therein
-
Novel cyano hydroxy pyridone monoazo yellow dye compounds are useful in thermoplastic electrostatographic toners. They absorb at the desired wavelength, are lightfast and have high tinctorial strength. They resist decomposition, sublimation and bleeding upon being thermally fixed to a substrate. For use in color transparencies, these dyes form a transparent toner image.
- -
-
-